Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
| Publication Type | Academic Article |
| Authors | Lorenc R, Shouval R, Flynn J, Devlin S, Saldia A, De Abia A, De Lapuerta M, Tomas A, Cassanello G, Leslie L, Rejeski K, Lin R, Scordo M, Shah G, Palomba M, Salles G, Park J, Giralt S, Perales M, Ip A, Dahi P |
| Journal | Transplant Cell Ther |
| Volume | 30 |
| Issue | 10 |
| Pagination | 990-1000 |
| Date Published | 07/06/2024 |
| ISSN | 2666-6367 |
| Keywords | Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Antigens, CD19 |
| Abstract | Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T cell therapy is becoming more relevant. The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL. We retrospectively studied 355 patients from 2 different medical centers treated with four different CAR T cell products from 2016 to 2022. The overall cumulative incidence for subsequent malignancies at 36 months was 14% (95% CI: 9.2%, 19%). Subsequent malignancies were grouped into 3 primary categories: solid tumor, hematologic malignancy, and dermatologic malignancy with cumulative incidences at 36 months of 6.1% (95% CI: 3.1%-10%), 4.5% (95% CI: 2.1%-8.1%) and 4.2% (95% CI: 2.1%-7.5%) respectively. Notably, no cases of T cell malignancies were observed. In univariable analysis, increasing age was associated with higher risk for subsequent malignancy. While the overall benefits of CAR T products continue to outweigh their potential risks, more studies and longer follow ups are needed to further demonstrate the risks, patterns, and molecular pathways that lead to the development of subsequent malignancies. |
| DOI | 10.1016/j.jtct.2024.06.027 |
| PubMed ID | 38972512 |
| PubMed Central ID | PMC11427145 |